Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Botulinum Toxin in Movement Disorders: An Update.
Anandan C, Jankovic J. Anandan C, et al. Toxins (Basel). 2021 Jan 8;13(1):42. doi: 10.3390/toxins13010042. Toxins (Basel). 2021. PMID: 33430071 Free PMC article. Review.
Botulinum toxin treatment in parkinsonism.
Anandan C, Jankovic J. Anandan C, et al. J Neurol Sci. 2024 Jan 15;456:122810. doi: 10.1016/j.jns.2023.122810. Epub 2023 Nov 26. J Neurol Sci. 2024. PMID: 38056063 Review.
Diagnostic pathways for breast cancer in 10 International Cancer Benchmarking Partnership (ICBP) jurisdictions: an international comparative cohort study based on questionnaire and registry data.
Vedsted P, Weller D, Zalounina Falborg A, Jensen H, Kalsi J, Brewster D, Lin Y, Gavin A, Barisic A, Grunfeld E, Lambe M, Malmberg M, Turner D, Harland E, Hawryluk B, Law RJ, Neal RD, White V, Bergin R, Harrison S, Menon U; ICBP Module 4 Working Group; ICBP Module 4 Academic Reference Group. Vedsted P, et al. BMJ Open. 2022 Dec 15;12(12):e059669. doi: 10.1136/bmjopen-2021-059669. BMJ Open. 2022. PMID: 36521881 Free PMC article.
Trial of Prasinezumab in Early-Stage Parkinson's Disease.
Pagano G, Taylor KI, Anzures-Cabrera J, Marchesi M, Simuni T, Marek K, Postuma RB, Pavese N, Stocchi F, Azulay JP, Mollenhauer B, López-Manzanares L, Russell DS, Boyd JT, Nicholas AP, Luquin MR, Hauser RA, Gasser T, Poewe W, Ricci B, Boulay A, Vogt A, Boess FG, Dukart J, D'Urso G, Finch R, Zanigni S, Monnet A, Pross N, Hahn A, Svoboda H, Britschgi M, Lipsmeier F, Volkova-Volkmar E, Lindemann M, Dziadek S, Holiga Š, Rukina D, Kustermann T, Kerchner GA, Fontoura P, Umbricht D, Doody R, Nikolcheva T, Bonni A; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. N Engl J Med. 2022 Aug 4;387(5):421-432. doi: 10.1056/NEJMoa2202867. N Engl J Med. 2022. PMID: 35921451 Clinical Trial.
Diagnostic routes and time intervals for ovarian cancer in nine international jurisdictions; findings from the International Cancer Benchmarking Partnership (ICBP).
Menon U, Weller D, Falborg AZ, Jensen H, Butler J, Barisic A, Knudsen AK, Bergin RJ, Brewster DH, Cairnduff V, Fourkala EO, Gavin AT, Grunfeld E, Harland E, Kalsi J, Law RJ, Lin Y, Turner D, Neal RD, White V, Harrison S, Reguilon I, Lynch C, Vedsted P; ICBP Module 4 Working Group. Menon U, et al. Br J Cancer. 2022 Sep;127(5):844-854. doi: 10.1038/s41416-022-01844-0. Epub 2022 May 26. Br J Cancer. 2022. PMID: 35618787 Free PMC article.
36 results